Individual DNA testing

Major future leaps in longevity will most likely result from developments in molecular biology and genomics.  And, on a practical level individual DNA testing will sooner or later play a major role simply because our genomes are different. 

After several years of nothing much happening, individual DNA testing is slowly entering the mainstream. On the medical side, applications include diagnosis of disease susceptibilities, tissue typing for organ transplantation, prenatal genetic assessment, assessments in cardiology and oncology, and screening for infectious diseases. On the consumer side, popular applications include paternity testing and testing for HIV; such tests are sold via Internet. And of course there are niche markets such as in forensics.  The cost-effectiveness of DNA testing is rapidly improving as is the range of applications, and within a five-year period. Individual DNA testing will probably have expanded by an order or two of magnitude.  According to an article in GEN, “The Sky Could Be The Limit For DNA Testing.” 

The traditional technology for DNA testing uses a technique called PCR standing for polymerase chain reaction.  PCR is a technique used to multiply one or a few pieces of DNA in a couple of hours into millions or more copies.  It works even when the source DNA is of relatively poor quality and it has become one of the most widely used laboratory techniques in molecular biology. Plain PCR is a labor-intensive multistep process that can be done for specific screening purpose in a lab but not in an ordinary kitchen.  Some companies, Roche Molecular diagnostics in particular, have developed technological “platforms” which automate the major steps of PCR.  For example “The COBAS® AMPLICOR Analyzer is the first benchtop system to fully automate the amplification and detection steps of the Polymerase Chain Reaction (PCR) testing process on a single instrument. It combines five instruments into one (thermal cycler, automatic pipettor, incubator, washer and reader).”  A number of other platforms for DNA amplification and molecular testing are being developed.  They include microarrays, beadarrays, and electrochemical arrays and may some day displace PCR.  Their cost-effectiveness and user-friendliness continue to improve.  But so far PCR remains the main technology with Roch Molecular Diagnostics enjoying by far the biggest slice of the market. 

As time moves on and the diagnostic processes become simpler and less expensive, more and more medical labs are acquiring molecular diagnostic capabilities.  Short-term driving forces include lower cost and simpler test units, units capable of doing multiple kinds of tests, and desire for faster turnaround time than possible if the tests have to be outsources. Today, in the infectious disease and oncology areas, traditional biochemical testing still is the dominant mode, with molecular testing representing only 20%-30% of the market, but the molecular/genetic testing continues to gain market share. 

In the news and frequently reported  in this Blog, there is a steady stream of research reports linking diseases to genes and gene polymorphisms and indicating new molecular therapy targets.  There is an accelerating need for individual genetic testing if the fruits of such research are to be harvested.  A longer-term driving force for widespread adoption of individual DNA testing is the slow emergence of personalized molecular-based medicine for assessing disease susceptibilities, disease detection, disease course prognosis, and prediction of patient drug response.  I think this shift in paradigm may require 20 or more years before it is firmly in the forefront.  Clearly this paradigm shift will have a major impact on protecting the health and extending the lives of those who will benefit from it. 

Of course there are other segments of DNA analysis besides tests designed to helped individuals.  There has been enormous progress in development of automated technologies for analyzing entire genomes.  An example is Affymetrix’s microarray-based Gene Titan  system. 

Molecular laboratory testing is already a big business.  The Gen article quotes a source (Kalorama) indicating estimating the 2007 worldwide market for molecular assays to be $3.7 billion.   The market is projected to grow at an 11% annual rate, reaching $6.2 billion in 2012.  Certain segments of this market are expected to grow at much higher rates.   The highest-growth areas of DNA testing according to the GEN article are pharmacogenomics (35%), inherited disease testing (25%), oncology and infectious diseases. 

In previous postings I have compared the rate of progress in the computer field in 1956 with the rate of progress in genomics and longevity science today.  Personalized diagnostic testing today is playing a transformative role today in medicine as developments in computer memories did back then.  Both then and today, scientific and commercial developments strongly supported each other.  It will be a while before we have the analog of the PC revolution, however, when everyone does their own DNA testing in their homes using inexpensive kits.  I fully expect this to happen within 20 years or so, however.

About Vince Giuliano

Being a follower, connoisseur, and interpreter of longevity research is my latest career, since 2007. I believe I am unique among the researchers and writers in the aging sciences community in one critical respect. That is, I personally practice the anti-aging interventions that I preach and that has kept me healthy, young, active and highly involved at my age, now 93. I am as productive as I was at age 45. I don’t know of anybody else active in that community in my age bracket. In particular, I have focused on the importance of controlling chronic inflammation for healthy aging, and have written a number of articles on that subject in this blog. In 2014, I created a dietary supplement to further this objective. In 2019, two family colleagues and I started up Synergy Bioherbals, a dietary supplement company that is now selling this product. In earlier reincarnations of my career. I was Founding Dean of a graduate school and a full University Professor at the State University of New York, a senior consultant working in a variety of fields at Arthur D. Little, Inc., Chief Scientist and C00 of Mirror Systems, a software company, and an international Internet consultant. I got off the ground with one of the earliest PhD's from Harvard in a field later to become known as computer science. Because there was no academic field of computer science at the time, to get through I had to qualify myself in hard sciences, so my studies focused heavily on quantum physics. In various ways I contributed to the Computer Revolution starting in the 1950s and the Internet Revolution starting in the late 1980s. I am now engaged in doing the same for The Longevity Revolution. I have published something like 200 books and papers as well as over 430 substantive.entries in this blog, and have enjoyed various periods of notoriety. If you do a Google search on Vincent E. Giuliano, most if not all of the entries on the first few pages that come up will be ones relating to me. I have a general writings site at and an extensive site of my art at Please note that I have recently changed my mailbox to
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply